Jefferies Global Healthcare Conference
Logotype for Fate Therapeutics Inc

Fate Therapeutics (FATE) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Fate Therapeutics Inc

Jefferies Global Healthcare Conference summary

18 Nov, 2026

CAR T platform and access

  • CAR T-cells were presented as living drugs that expand in response to disease burden, unlike conventional medicines whose effects can decline over time.

  • The off-the-shelf platform is designed for safety, scalable manufacturing, broad access and outpatient delivery, with a goal of extending CAR T use into rheumatology and other inflammatory or fibrotic diseases.

  • iPSC clone selection creates a uniform starting cell for manufacturing; the master cell bank approach is intended to support consistent, high-volume inventory.

  • A CAR T-cell dose was estimated at $3,000 at current inventory and volume levels, with cost expected to decline as production scales; current working volume is in the hundreds of liters.

FT819 in autoimmune disease

  • More than 35 patients had been treated; grade 1–2 CRS occurred in ~17%, while infection and cytopenia rates were described as very low with less intensive conditioning.

  • Clinical data showed rapid reductions in lupus disease activity and UPCR; standard-of-care medications were discontinued from day -5 before FT819 administration.

  • A potentially registrational lupus nephritis trial had started under FDA RMAT designation and CDRP inclusion: single-arm, 53 patients, one FT819 dose, and complete renal response at six months as the primary endpoint.

  • Three extrarenal lupus patients responded without conditioning chemotherapy; two achieved DORIS and one LLDAS. In a separate multi-dose case, SLEDAI fell from 10 to 2 within one month and LLDAS was reached by month two.

  • In systemic sclerosis, all patients achieved rCRISS of 25 or better, with skin scores improving; further trial updates were anticipated.

FT839 and broader autoimmune development

  • FT839 is designed to target activated, aberrant immune cells across cell types while sparing resting immune cells; its engineering targets CD19 and CD38.

  • The COMPLETE trial was recruiting and activating sites, with no conditioning chemotherapy planned; an update was expected early in 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Fate Therapeutics